On the Horizon – Estrogen Receptor Modulator Reduces Bone Complications from Androgen Deprivation Therapy for Prostate Cancer

A multi-center Phase III study was discussed at the 2009 meeting of the American Urological Association.[1] The perliminar results of this study has demonstrated that the risk for incurring bone fractures in men on androgen deprivation therapy (ADT) is reduced when the drug toremifene (Acapodene) is administered. Men, fighting advanced prostate cancer, often receive long-term [...]

Patient Care Costs in Clinical Trials – A Problem

Clinical trials are the lifeblood of new drug and treatment development. Trials allow us to learn what developing drugs and treatment are both safe and effective. Many drug developers complain about their inability to attract enough volunteers to reach a sample size that will allow them to draw statistically valid conclusions. Everyday there are trials [...]

On the Horizon – Sunitinib Malate for Metastatic Castration-Resistant Prostate Cancer Following Docetaxel Chemotherapy

Docetaxel (Taxotere), or chemotherapy, will as all other treatments for advanced prostate cancer stop working. Many of us will progress quickly to this stage and eventually face a situation where there are no longer any approved treatments available to control our prostate cancer. If you are lucky enough to have an oncologist who is creative [...]

A Telephone Workshop on Metastatic Prostate Cancer

Cancer Care is conducting a telephone workshop on Metastatic Prostate Cancer on Tuesday, September 22, 2009 from 1:30 to 2:30 eastern time. Listening in on the workshop is free. Participants in the workshop will be: Susan Slovin MD, PhD, Associate Attending Physician, Genitourinary Oncology Service, Sidney Kimmel Center for the Treatment of Prostate & Urologic [...]

Combining Radiopharmaceuticals and Bisphosphonates to Treat Bone Mets

A recent study of one man at the Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, The Netherlands combined both treatment modalities, radiopharmaceuticals and bisphosphonates, to combat bone pain caused by bone metastases. Their results were surprising. Bone-seeking radiopharmaceuticals and bisphosphonates are both an indicated treatment for men with prostate cancer when painful [...]

Go to Top